Can EHRs offer personalized care to every patient?

Cara Livernois | | Health Exec | EMR/EHR

The potential for electronic health records (EHRs) to streamline healthcare has been promised for years—but EHRs may have the ability to personalize treatment for every patient.

NPR's Richard Harris outlines EHR advancements in some of the biggest healthcare companies such as Kaiser Permanente and Geisinger Health System.

"Patients are always saying, 'Don't just give me the averages, tell me what happened to others who look like me and made the same treatment decisions I did,'" said Tracy Lieu, MD, MPH, head of Kaiser's research division. "And tell me not only did they live or die, but tell me what their quality of life was about."

EHRs could soon be a type of search engine. A patient, for example, could search for “pancreatic cancer” and have treatment histories from various healthcare systems. Users can further specialize their search by checking off topics centered on cancer stage, patient age, type of treatment and outcomes.

Read the full article by clicking the link below:

Electronic Health Records May Help Customize Medical Treatments

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care
How are the best in KLAS Health IT vendor rankings created?

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup